Building a best-in-class biologics company dedicated to improving the patient experience
ValenzaBio is building a highly competitive monoclonal antibody (mAb) company, with a suite of best-in-class biologics that will offer clear advantages to doctors, patients, and their loved ones. With three clinical product candidates being advanced for a range of conditions in ophthalmic, dermatologic, and renal conditions, and discovery programs following, we are on track to have medicines commercially available in 2026.
VB421 and VB119, currently in clinical trials, utilize well-understood mechanisms of action, minimizing clinical risk and accelerating the approval pathway in ophthalmic and renal indications respectively.
VB517, which we hope to advance to the clinic next year, likewise has the best potency in its class, which we believe will allow us to compete in both dermatological and allergic indications.
VB380, our discovery-stage program, targets a surface marker on cells that we believe may provide an alternative therapeutic approach in multiple autoimmune diseases where patients need better options.
Our programs target different indications but share common advantages
- Were originally developed in oncology, often as targeting molecules for ADCs, and have extensive data in patients or preclinical models
- Have well understood and recognized mechanisms of action
- Address markets with patient populations that have shown benefit from our approach, either via a competitor product or from an off-label validator
- Feature best-in-class potency, binding affinity, or autoantibody depletion properties
- VB421 and VB517 have been enabled and formulated from inception for subcutaneous administration in Phase I clinical trials
- Are supported by agreements in place with world-class biomanufacturing facilities
- Feature direct traditional approval pathways with accepted endpoints and clinical trial approaches
- Serve patient populations seeking improved options over existing therapies
- Provide competition to incumbent therapies by providing patients with better options
ADC=antibody-drug conjugate; CMC=chemistry, manufacturing and controls.
MANAGEMENT TEAM
Patrick J. Crutcher, MSc
Co-Founder, Chief Executive Officer, Member of Board of Directors
David Maizenberg, JD
Co-Founder, General Counsel, Member of Board of Directors
Stephen Thomas, PhD
Chief Scientific Officer
Tatyana Touzova, MSc
Chief Operating Officer
Greg Keenan, MD
Chief Medical Officer
William Bonificio, PhD
Chief Strategy Officer
Keri Lantz, CPA
Vice President, Head of Finance
BOARD OF DIRECTORS
Patrick J. Crutcher, MSc
David Maizenberg, JD
Mike Solomon, PhD
John Doux, MD
SCIENTIFIC ADVISORY BOARD
Raymond Douglas, MD, PhD
Jamie Dwyer, MD
Stephen Thomas, PhD
Greg Keenan, MD
GET IN TOUCH
6701 Democracy Blvd.
Suite 300
Bethesda, MD 20817